Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal MelanomaC. Mignard, P. Joly, Aurélie Deschamps Huvier et al.|Journal of Oncology|2018Cited by 82
Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohortM. Kandel, Isabelle Borget, Stéphane Dalle et al.|European Journal of Cancer|2018Cited by 38
Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case–control studyLéo Plaçais, Célèste Lebbé, Stéphane Dalle et al.|Annals of the Rheumatic Diseases|2022Cited by 34
Combined Therapy with Anti-PD1 and BRAF and/or MEK Inhibitor for Advanced Melanoma: A Multicenter Cohort StudySandra Huynh, Julie Delyon, Laurent Mortier et al.|Cancers|2020Cited by 21
Quality‐of‐life assessment in French patients with metastatic melanoma in real lifeM. Kandel, Isabelle Borget, Stéphane Dalle et al.|Cancer|2019Cited by 14